254
Participants
Start Date
September 8, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
HH2853 Tablets
Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
COMPLETED
Mayo Clinic, Jacksonville
COMPLETED
Mayo Clinic, Rochester
COMPLETED
NEXT Oncology, San Antonio
COMPLETED
Mayo Clinic, Phoenix
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Anhui Medical University, Hefei
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Beijing Jishuitan Hospital, Beijing
RECRUITING
Sun Yat-Sen University Cancer Hospital, Guangzhou
RECRUITING
Affiliated Tumor Hospital of Guangxi Medical University, Nanning
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing
RECRUITING
Liaoning Cancer Hospital&Institute, Shenyang
RECRUITING
Shengjing Hospital Of China Medical University, Shenyang
RECRUITING
Linyi Tumor Hospital, Linyi
RECRUITING
Shanghai Sixth People's Hospital, Shanghai
RECRUITING
Zhongshan Hospital Fudan University, Shanghai
RECRUITING
Shanxi Cancer Hospital, Taiyuan
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Tianjin Cancer Hospital, Tianjin
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Sun Yat-Sen University Cancer Hospital, Guangzhou
Lead Sponsor
Haihe Biopharma Co., Ltd.
INDUSTRY